氢化可的松对重症COVID-19患者21天死亡率或呼吸支持的影响:一项随机临床试验
这项在法国开展的多中心随机双盲序贯试验纳入149例因COVID-19相关急性呼吸衰竭入住ICU的患者,随机接受低剂量氢化可的松(n=76)或安慰剂(n=73)。主要终点为21天治疗失败(死亡或持续依赖机械通气或高流量氧疗),氢化可的松组42.1% vs 安慰剂组50.7%(差异-8.6%,95.48%CI -24.9%至7.7%,P=0.29),无显著差异。4项预设次要终点均无显著差异,无与研究治疗相关的严重不良事件。研究因数据与安全监察委员会建议提前终止,可能统计效能不足以检出具有统计学和临床意义的差异。
要点
- 在重症COVID-19急性呼吸衰竭患者中,低剂量氢化可的松组21天治疗失败率42.1%(32/76),安慰剂组50.7%(37/73),差异-8.6%(95.48%CI -24.9%至7.7%),无统计学显著差异。
- 氢化可的松组死亡11例,安慰剂组死亡20例;共69例治疗失败事件。
- 4项预设次要终点(气管插管需求、俯卧位通气、ECMO、吸入一氧化氮累积发生率、PaO2:FiO2比值、继发感染比例)均无显著差异。
- 无与研究治疗相关的严重不良事件。
- 研究纳入149例后提前终止,原文指出可能统计效能不足,未能检出具有统计学和临床意义的差异。
适用人群与场景
- 因COVID-19相关急性呼吸衰竭入住ICU的成人患者;纳入时间2020年3月7日至6月1日,末次随访2020年6月29日。
- 平均年龄62.2岁,女性占30.2%,81.2%接受机械通气。
诊断标准与关键阈值
- 主要终点治疗失败定义为第21天死亡或持续依赖机械通气或高流量氧疗。
处置流程与药物剂量
- 低剂量氢化可的松(n=76)与安慰剂(n=73)比较;原文未给出具体剂量、给药途径和疗程。
研究设计与关键结果
- 多中心随机双盲序贯试验,计划纳入290例,每50例进行中期分析;实际纳入149例后因数据与安全监察委员会建议提前终止。
- 主要终点21天治疗失败:氢化可的松组32/76(42.1%) vs 安慰剂组37/73(50.7%),差异-8.6%(95.48%CI -24.9%至7.7%),P=0.29。
- 死亡:氢化可的松组11例,安慰剂组20例;共69例治疗失败事件。
- 4项预设次要终点均无显著差异;无与研究治疗相关的严重不良事件。
证据类型、等级与局限
- 证据类型:多中心随机双盲序贯试验。
- 局限:研究提前终止,可能统计效能不足以检出具有统计学和临床意义的差异(原文自述)。
对床旁实践的改变
- 作者结论:在重症COVID-19急性呼吸衰竭患者中,与安慰剂相比,低剂量氢化可的松未显著降低21天治疗失败率。
- 原文未据此给出推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Coronavirus disease 2019 (COVID-19) is associated with severe lung damage. Corticosteroids are a possible therapeutic option.
OBJECTIVE: To determine the effect of hydrocortisone on treatment failure on day 21 in critically ill patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and acute respiratory failure.
DESIGN, SETTING, AND PARTICIPANTS: Multicenter randomized double-blind sequential trial conducted in France, with interim analyses planned every 50 patients. Patients admitted to the intensive care unit (ICU) for COVID-19-related acute respiratory failure were enrolled from March 7 to June 1, 2020, with last follow-up on June 29, 2020. The study intended to enroll 290 patients but was stopped early following the recommendation of the data and safety monitoring board.
INTERVENTIONS: Patients were randomized to receive low-dose hydrocortisone (n = 76) or placebo (n = 73).
MAIN OUTCOMES AND MEASURES: The primary outcome, treatment failure on day 21, was defined as death or persistent dependency on mechanical ventilation or high-flow oxygen therapy. Prespecified secondary outcomes included the need for tracheal intubation (among patients not intubated at baseline); cumulative incidences (until day 21) of prone position sessions, extracorporeal membrane oxygenation, and inhaled nitric oxide; Pao2:Fio2 ratio measured daily from day 1 to day 7, then on days 14 and 21; and the proportion of patients with secondary infections during their ICU stay.
RESULTS: The study was stopped after 149 patients (mean age, 62.2 years; 30.2% women; 81.2% mechanically ventilated) were enrolled. One hundred forty-eight patients (99.3%) completed the study, and there were 69 treatment failure events, including 11 deaths in the hydrocortisone group and 20 deaths in the placebo group. The primary outcome, treatment failure on day 21, occurred in 32 of 76 patients (42.1%) in the hydrocortisone group compared with 37 of 73 (50.7%) in the placebo group (difference of proportions, -8.6% [95.48% CI, -24.9% to 7.7%]; P = .29). Of the 4 prespecified secondary outcomes, none showed a significant difference. No serious adverse events were related to the study treatment.
CONCLUSIONS AND RELEVANCE: In this study of critically ill patients with COVID-19 and acute respiratory failure, low-dose hydrocortisone, compared with placebo, did not significantly reduce treatment failure (defined as death or persistent respiratory support) at day 21. However, the study was stopped early and likely was underpowered to find a statistically and clinically important difference in the primary outcome.
TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02517489.
参考来源
- Dequin PF, Heming N, Meziani F, et al. Effect of Hydrocortisone on 21-Day Mortality or Respiratory Support Among Critically Ill Patients With COVID-19: A Randomized Clinical Trial. JAMA. 2020. PMID: 32876689. doi:10.1001/jama.2020.16761
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。